PC23546C

Terminal Disclaimer Submitted in Response to Restriction Requirement and Terminal Disclaimers

Certificate of Mailing (37 C.F.R. §1.8): I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop:

Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 21st day of March 2006.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

MALCOLM WILSON MOON, ET AL.

Serial No.: 10/774,415

Filed: February 10, 2004

For: PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE

DERIVATIVES

Group Art Unit: 1626

Examiner: Kamal A. Saeed

Confirmation No. 9923

Attorney Docket No.: PC23546C

Mail Stop: Amendment **Commissioner For Patents** P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Amendments and Response

2. Terminal Disclaimer over US Patent No. 6,716,870

3. Terminal Disclaimer over US Patent No. 6,482,848

4. Fee Transmittal + duplicate

5. Return Postcard

6. Total Fee Due (\$260.00)

12 pages;

1 page;

1 page;

1 page + duplicate;

1 postcard; and

Deposit Account.

Respectfully submitted,

Mar. 21, 200

Ye Hua

Attorney For Applicants Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-3020

Fax: (858) 678-8233

Approved for use through 07/31/2006. OMB 0651-0032

Inder the Partiwork Reduction Act of 1995, no persons are required to re	spond to a collection of infor	mation unless it displays a valid OMB control number
		Complete if Known
Effective on 12/08/2004. Frank of the Consolidated Appropriations Act, 2005 (H.R. 4818).	Application Number	10/774,415
FEE TRANSMITTAL	Filing Date	February 10, 2004
For FY 2005	First Named Inventor	Malcolm Wilson Moon
	Examiner Name	Kamal A. Saeed
Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1626
TOTAL AMOUNT OF PAYMENT (\$) 260.00	Attorney Docket No.	PC23546C
METHOD OF PAYMENT (check all that apply)		
Check Credit Card Money Order Nor		
✓ Deposit Account Deposit Account Number: 500329		ame: Agouron Pharmaceuticals
For the above-identified deposit account, the Director is he		
Charge fee(s) indicated below	_) indicated below, except for the filing fee
Charge any additional fee(s) or underpayments of feunder 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card in information and authorization on PTO-2038.		
FEE CALCULATION		
1. BASIC FILING, SEARCH, AND EXAMINATION FEES FILING FEES SEAF Small Entity	RCH FEES EXA Small Entity	MINATION FEES Small Entity
Application Type Fee (\$) Fee (\$)		Fees Paid (\$)
Utility 300 150 500	250 20	0 100
Design 200 100 100	50 13	0 65
Plant 200 100 300	150 16	0 80
Reissue 300 150 500	250 60	0 300
Provisional 200 100 0	0	0 · 0
2. EXCESS CLAIM FEES Fee Description Each claim over 20 (including Reissues) Each independent claim over 3 (including Reissues) Multiple dependent claims		Small Entity Fee (\$) Fee (\$) 50 25 200 100 360 180
<u>Total Claims</u> <u>Extra Claims</u> <u>Fee (\$)</u> <u>Fe</u>	e Paid (\$)	Multiple Dependent Claims Fee (\$) Fee Paid (\$)
- 3 or HP = x =	e Paid (\$)	<u>Fee (\$)</u>
HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paid listings under 37 CFR 1.52(e)), the application size of sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) Total Sheets Extra Sheets Number of each sheet s	ee due is \$250 (\$125 f	tion thereof Fee (\$) Fee Paid (\$)
4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity)		Fees Paid (\$)
Other (e.g., late filing surcharge): Statutory Disclaimer (Fee Code 1814/2814 37	C.F.R. 1.20(d)) \$260.00

SUBMITTED BY	was a second		
Signature	Unlhis	Registration No. (Attorney/Agent) 53,042	Telephone 858-622-3020
Name (Print/Type) Ye	14)	y manny, igony	Date March 21, 2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.